Sai Life Science hit a new high of ₹1,578, gaining 4% on Wednesday's intra-day trading, extending its previous day's upward momentum on healthy business outlook. According to reports from Business Standard, the stock has demonstrated exceptional performance with a 19% surge in the past month, significantly outperforming the 2.8% decline in the BSE Sensex during the same period. The pharmaceutical company's stock has zoomed 80% in the past seven months, showcasing sustained investor confidence in the sector's growth prospects. In the latest market session, more than 160 stocks touched 52-week highs, including Sai Life Sciences, with the broader market experiencing significant volatility amid sector-wise movements.
The stock's performance was accompanied by exceptional trading activity, with the average trading volume more than doubling to a combined 1.4 million equity shares changing hands on both NSE and BSE exchanges. As reported by Business Standard, this surge in trading volume reflects heightened investor interest and the stock's strong momentum in the current market environment. The broader market underperformed benchmark indices, with Nifty midcap index falling 1.4% and smallcap index down 0.2%, while the Nifty ended 25 points lower amid volatile trading conditions.
According to Moneycontrol Pro, Sai Life Science is positioning for macrocyclic peptides, PDCs, and radiochemistry applications by aligning its capital expenditure strategy. The company is aligning its capital expenditure to capitalize on these emerging opportunities in the pharmaceutical sector. This strategic positioning reflects the company's proactive approach to capturing growth in specialized pharmaceutical applications, particularly in the high-value peptide and radiochemistry segments.
As reported by Business Standard, the CRDMO sector collectively delivered 19% year-on-year growth, the highest in the past 7 quarters, led by companies including Divi's Labs, Laurus Labs, Gland Pharma, Piramal Pharma, and Sai Life Science. The sector is projected to register a strong compound annual growth rate (CAGR) of 15–16% between calendar year 2026 and CY2035, with the market expected to reach $7–9 billion by CY2030 and further to $14–18 billion by CY2035. Sai Life Science has indicated strong revenue visibility with 90% plus of its targeted FY27 revenue covered by orders in hand.
According to Business Standard, analysts maintain a 'Buy' rating on Sai Life Science with a target price of ₹1,610 per share. The company's dedicated peptide development lab is expected to come online shortly and will have the capability to deliver clinical batches. In FY28, Sai Life plans to break ground on a Greenfield peptide manufacturing facility. The management commentary indicates strong request for proposal (RFP) inflows from Big Pharma companies, alongside high order book visibility for the current year, with FY27 revenue split expected to be 40:60 between H1 and H2. However, as noted by Moneycontrol Pro, the stock's rich valuation presents a concern for investors despite the strong fundamentals and growth prospects.
